Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including beta-lactam. I...
Orchid Pharma reported revenue of 9.14 billion INR for fiscal year 2025, up 11.6% from fiscal year 2024, and net income of 996.57 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 2.07 billion INR, down 4.6% from a year before. Rest of the World was its largest region in fiscal year 2025, with 80% of revenue. Its market capitalization was 49.91 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.